Cidara Therapeutics (CDTX) Competitors $17.90 +2.78 (+18.39%) (As of 09:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CDTX vs. NTGN, XFOR, SCYX, AGTC, MREO, GLUE, PROK, ZVRA, ESPR, and RGNXShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Neon Therapeutics (NTGN), X4 Pharmaceuticals (XFOR), SCYNEXIS (SCYX), Applied Genetic Technologies (AGTC), Mereo BioPharma Group (MREO), Monte Rosa Therapeutics (GLUE), ProKidney (PROK), Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), and REGENXBIO (RGNX). These companies are all part of the "medical" sector. Cidara Therapeutics vs. Neon Therapeutics X4 Pharmaceuticals SCYNEXIS Applied Genetic Technologies Mereo BioPharma Group Monte Rosa Therapeutics ProKidney Zevra Therapeutics Esperion Therapeutics REGENXBIO Neon Therapeutics (NASDAQ:NTGN) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Which has more risk and volatility, NTGN or CDTX? Neon Therapeutics has a beta of -0.81, suggesting that its stock price is 181% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Which has stronger valuation & earnings, NTGN or CDTX? Cidara Therapeutics has higher revenue and earnings than Neon Therapeutics. Neon Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeon TherapeuticsN/AN/A-$79.78M-$2.86-1.07Cidara Therapeutics$63.90M1.97-$22.93M-$25.52-0.70 Does the media prefer NTGN or CDTX? In the previous week, Cidara Therapeutics had 6 more articles in the media than Neon Therapeutics. MarketBeat recorded 6 mentions for Cidara Therapeutics and 0 mentions for Neon Therapeutics. Cidara Therapeutics' average media sentiment score of 0.53 beat Neon Therapeutics' score of 0.00 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neon Therapeutics Neutral Cidara Therapeutics Positive Do analysts prefer NTGN or CDTX? Cidara Therapeutics has a consensus price target of $30.50, indicating a potential upside of 70.39%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than Neon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders and institutionals have more ownership in NTGN or CDTX? 54.7% of Neon Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 38.9% of Neon Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is NTGN or CDTX more profitable? Neon Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -69.64% beat Neon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neon TherapeuticsN/A -199.09% -137.14% Cidara Therapeutics -289.05%-69.64%-33.73% Does the MarketBeat Community believe in NTGN or CDTX? Cidara Therapeutics received 278 more outperform votes than Neon Therapeutics when rated by MarketBeat users. Likewise, 70.17% of users gave Cidara Therapeutics an outperform vote while only 67.87% of users gave Neon Therapeutics an outperform vote. CompanyUnderperformOutperformNeon TherapeuticsOutperform Votes16967.87% Underperform Votes8032.13% Cidara TherapeuticsOutperform Votes44770.17% Underperform Votes19029.83% SummaryCidara Therapeutics beats Neon Therapeutics on 14 of the 18 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.20M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-0.7016.1687.8613.46Price / Sales1.97282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book1.094.436.946.30Net Income-$22.93M-$41.63M$119.12M$225.93M7 Day Performance23.62%-4.73%-1.84%-1.32%1 Month Performance59.54%-6.53%-3.65%0.60%1 Year Performance22.18%25.63%31.64%26.23% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.1934 of 5 stars$17.90+18.4%$30.50+70.4%+0.9%$126.20M$63.90M-0.7090High Trading VolumeNTGNNeon TherapeuticsN/A$3.07flatN/AN/A$88.93MN/A-1.07102XFORX4 Pharmaceuticals4.0062 of 5 stars$0.34-0.4%$2.88+747.8%-57.4%$57.83MN/A0.0080Analyst RevisionSCYXSCYNEXIS2.2075 of 5 stars$1.17-1.3%N/A-28.5%$44.21M$140.14M0.0060Positive NewsAGTCApplied Genetic Technologies0.117 of 5 stars$0.39flatN/AN/A$26.62M$320,000.00-0.2783MREOMereo BioPharma Group2.9665 of 5 stars$3.58+2.6%$7.50+109.5%+63.5%$502.13M$10M0.0040Analyst RevisionNews CoverageGLUEMonte Rosa Therapeutics2.9694 of 5 stars$8.17-2.3%$16.00+95.8%+157.2%$501.97MN/A0.0090PROKProKidney2.5946 of 5 stars$1.66+0.6%$4.50+171.1%-6.3%$480.85MN/A0.003News CoverageZVRAZevra Therapeutics3.4632 of 5 stars$8.97flat$21.00+134.1%+100.2%$478.82M$27.46M-4.5565Analyst ForecastAnalyst RevisionESPREsperion Therapeutics3.9536 of 5 stars$2.40-0.4%$8.17+240.3%+97.5%$472.90M$116.33M-3.77240Analyst ForecastRGNXREGENXBIO4.4242 of 5 stars$9.53-1.0%$35.27+270.1%-51.9%$472.12M$90.24M-1.91344Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Neon Therapeutics Competitors X4 Pharmaceuticals Competitors SCYNEXIS Competitors Applied Genetic Technologies Competitors Mereo BioPharma Group Competitors Monte Rosa Therapeutics Competitors ProKidney Competitors Zevra Therapeutics Competitors Esperion Therapeutics Competitors REGENXBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDTX Stock Alerts